Affiliations 

  • 1 School of Pharmacy, International Medical University (IMU), Kuala Lumpur 57000, Malaysia
  • 2 Department of Pharmaceutical Chemistry, School of Pharmacy, International Medical University (IMU), Kuala Lumpur 57000, Malaysia; Centre for Bioactive Molecules and Drug Delivery, Institute for Research, Development and Innovation (IRDI), International Medical University (IMU), Kuala Lumpur 57000, Malaysia. Electronic address: vasudevaraoavupati@imu.edu.my
Biomed Pharmacother, 2022 Jan;145:112406.
PMID: 34785416 DOI: 10.1016/j.biopha.2021.112406

Abstract

Rhodanine has been recognized as a privileged scaffold in medicinal chemistry due to its well-known ability to demonstrate a broad range of biological activities. The possibility of structural diversification has contributed to the significance of rhodanine structure in effective drug discovery and design. Many studies have confirmed the potential of rhodanine-derived compounds in the treatment of different types of cancer through the apoptosis induction mechanism. Furthermore, most of the rhodanine derivatives exhibited remarkable anticancer activity in the micromolar range while causing negligible cytotoxicity to normal cells. This review critically describes the anticancer activity profile of reported rhodanine compounds and the structure-activity relationships (SAR) to highlight the value of rhodanine as the core structure for future cancer drug development as well as to assist the researchers in rational drug design.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.